PPD
Executive Summary
Genupro subsidiary has dapoxetine in Phase II trials for premature ejaculation, CEO Fred Eshelman reported during an April 21 conference call. The company has enrolled 138 of a planned 150 patients in the study. Proof of concept may be established in the third quarter, at which time Lilly has the option to re-license the drug in exchange for a milestone payment. Genupro was established last year to develop genitourinary compounds licensed from Lilly
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth